Scarica l'app Stockscreener
1,127.69
0.93%
10.43
Pre-mercato:
1124.19
-3.50
-0.31%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1,117.26
Aprire:
$1126.99
Volume 24 ore:
2.75M
Relative Volume:
0.88
Capitalizzazione di mercato:
$1.01T
Reddito:
$72.25B
Utile/perdita netta:
$25.28B
Rapporto P/E:
40.59
EPS:
27.781
Flusso di cassa netto:
$10.37B
1 W Prestazione:
+2.65%
1M Prestazione:
+5.89%
6M Prestazione:
+4.71%
1 anno Prestazione:
+42.33%
Intervallo 1D:
$1,114.00
$1,145.43
Intervallo di 1 settimana:
$1,079.22
$1,145.43
Portata 52W:
$623.78
$1,182.73
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,127.69 | 996.31B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
244.88 | 580.14B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
243.14 | 415.00B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
125.45 | 297.86B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.12 | 292.17B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Downgrade | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Reiterato | BofA Securities | Buy |
| 2025-12-15 | Reiterato | Goldman | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Lilly launches "The Memory Radio Station" across Europe, inviting the public to visually reconstruct fading memories through GenAI - PR Newswire
Eli Lilly (LLY) Acquires Centessa Pharmaceuticals to Advance Orexin Receptor 2 Agonists - Insider Monkey
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying - The Motley Fool
Nancy Pelosi Stock Tracker Flags Eli Lilly, Nokia After Trump Praise: ‘Keep An Eye On These Two’ - Yahoo Finance
Obesity drugs approach a major milestone, and Lilly may have a 'game changer' ahead - CNBC
LLY Maintained by Leerink Partners -- Price Target Raised to $12 - GuruFocus
Six months in, Lilly says its supercomputer is starting to change the work with ‘near-infinite’ AI tokens - R&D World
White House says Trump did not receive early access to new Lilly obesity drug - Indianapolis Business Journal
An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right? - The Motley Fool
Eli Lilly CEO announces Trump-backed Medicare program offering weight loss drugs for $50 a month - Fox Business
Eli Lilly (LLY) Announces Medicare Coverage for Obesity Medicati - GuruFocus
Eli Lilly CEO launches Medicare GLP-1 bridge program after working closely with Trump admin - Fox Business
Lilly taps Abbisko for $1.9B discovery deal - BioWorld News
Eli Lilly launches India's first RET-targeted therapy for solid tumours - Business Standard
Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success - Benzinga
5 Trending US Stocks to Buy Now - Insider Monkey
Eli Lilly (LLY) Expands Medicare GLP-1 Coverage for Weight Management - GuruFocus
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,232 - 富途牛牛
Eli Lilly launches cancer drug Tanstrive in India - The Economic Times
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management - PR Newswire
Eli Lilly suspends access to drug discounts for some hospitals - reporter.net
Eli Lilly & Co (NYSE:LLY) Screens as a Top Growth Stock with a Strong Technical Breakout Setup - ChartMill
Eli Lilly’s dispensing and delivery service LillyDirect comes to UK - Chemist+Druggist
Eli Lilly signs new partnership deal with China's Abbisko - medwatch.com
FTAV’s further reading - Financial Times
Eli Lilly and Company (LLY) – Among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors - Insider Monkey
Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration - Forbes
Lilly’s GLP-1 windfall fuels M&A ‘land grab’ across 10 deals, $25B - BioWorld News
Index Ventures entities exit Centessa (CNTA) stake as Eli Lilly acquisition closes - Stock Titan
Centessa (CNTA) sale to Eli Lilly at $38 plus CVR detailed in Form 4 - Stock Titan
Eli Lilly dives into hair loss treatments with investment in AI startup Absci - statnews.com
Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain (NASDAQ:ABSI) - Seeking Alpha
White House bats down speculation that Trump got access to Eli Lilly obesity drug - NewsNation
Portland-area biotech receives $100M investment led by Eli Lilly - The Business Journals
Lilly Completes Centessa Acquisition to Expand Sleep Disorder Drug Pipeline - citybiz
At BIO, a glimpse behind Lilly and Chai’s partnership - statnews.com
Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact - Benzinga
Lilly Expands AI Drug Discovery Push With ‘App Store’ Model For Biotech Scientists - Pulse 2.0
Eli Lilly (NYSE:LLY): What Does The Abbisko Deal Mean? - Kalkine Media
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders - investor.lilly.com
Abbisko Therapeutics, Lilly Expand R&D Alliance - Contract Pharma
LLY or PFE: Which Drugmaker Offers the Stronger Growth Story? - The Globe and Mail
Eli Lilly and Abbisko Announce Drug Development Collaboration - PharmExec.com
Is Eli Lilly and Company (LLY) Strengthening Its Pain Management Strategy With New Biotech Acquisition? - Insider Monkey
NYSE Content Update: Abridge Partners with Eli Lilly, Nvidia to Improve Healthcare - 巴士的報
Lilly closes Centessa deal to pursue narcolepsy and sleep-wake drugs - Stock Titan
Abbisko Therapeutics Partners with Eli Lilly (LLY) for $1.9B R&D Collaboration - GuruFocus
Eli Lilly reunites with Abbisko in $1.9B, multitarget R&D pact - Fierce Biotech
White House Denies Report Linking Trump To Eli Lilly's Experimental Obesity Treatment: 'Not For The President' - Benzinga
Eli Lilly (LLY) Invests in AI Drug Development Amid Patent Expirations - GuruFocus
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says - Reuters
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):